Robert Kirken to Fusion Proteins, bcr-abl
This is a "connection" page, showing publications Robert Kirken has written about Fusion Proteins, bcr-abl.
Connection Strength
0.565
-
Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Tumour Biol. 2016 Sep; 37(9):12643-12654.
Score: 0.565